TSE:HLS HLS Therapeutics (HLS) Stock Price, News & Analysis → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free HLS Stock Alerts C$3.94 -0.20 (-4.83%) (As of 05/17/2024 ET) Add Compare Share Share Today's RangeC$3.94▼C$3.9650-Day RangeC$3.61▼C$5.1752-Week RangeC$3.34▼C$7.12Volume411 shsAverage Volume8,551 shsMarket CapitalizationC$125.65 millionP/E RatioN/ADividend Yield5.08%Price TargetC$3.88 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider Trades Get HLS Therapeutics alerts: Email Address HLS Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside1.6% DownsideC$3.88 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingAcquiring SharesC$7,250 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.30 out of 5 stars 1.1 Analyst's Opinion Consensus RatingHLS Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageHLS Therapeutics has received no research coverage in the past 90 days.Read more about HLS Therapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for HLS. Previous Next 1.7 Dividend Strength Dividend LeadershipHLS Therapeutics is a leading dividend payer. It pays a dividend yield of 4.30%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthHLS Therapeutics does not have a long track record of dividend growth.Read more about HLS Therapeutics' dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HLS. Previous Next 1.8 News and Social Media Coverage News SentimentHLS Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for HLS Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows1 people have added HLS Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, HLS Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$7,250.00 in company stock and sold C$0.00 in company stock.Percentage Held by InsidersOnly 0.49% of the stock of HLS Therapeutics is held by insiders.Percentage Held by Institutions59.68% of the stock of HLS Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about HLS Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of HLS Therapeutics is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HLS Therapeutics is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHLS Therapeutics has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about HLS Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. About HLS Therapeutics Stock (TSE:HLS)HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.Read More HLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HLS Stock News HeadlinesMay 12, 2024 | americanbankingnews.comHLS Therapeutics (TSE:HLS) Price Target Cut to C$3.75May 12, 2024 | americanbankingnews.comHLS Therapeutics (TSE:HLS) PT Lowered to C$4.00May 9, 2024 | morningstar.comHLS Therapeutics Inc HLSMay 9, 2024 | finance.yahoo.comHLS Therapeutics Announces Q1 2024 Financial ResultsApril 9, 2024 | finance.yahoo.comHLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 8, 2024 | finance.yahoo.comNew REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsMarch 17, 2024 | finance.yahoo.comEarnings Release: Here's Why Analysts Cut Their HLS Therapeutics Inc. (TSE:HLS) Price Target To CA$6.57March 14, 2024 | finance.yahoo.comHLS Therapeutics Inc. (TSE:HLS) stock most popular amongst retail investors who own 40%, while hedge funds hold 39%March 14, 2024 | finance.yahoo.comHLS Therapeutics Announces Fiscal 2023 Financial ResultsMarch 13, 2024 | markets.businessinsider.comHLS Therapeutics earnings: here's what to expectFebruary 21, 2024 | finance.yahoo.comSeveral Insiders Invested In HLS Therapeutics Flagging Positive NewsFebruary 6, 2024 | ca.finance.yahoo.comStocks in play: HLS Therapeutics Inc.February 6, 2024 | finance.yahoo.comHLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug PlanDecember 20, 2023 | msn.comPharma breakthroughs: 10 novel drug approvals that made headlines in 2023December 18, 2023 | marketwatch.comHLS Therapeutics CFO Tim Hendrickson to Step DownDecember 18, 2023 | msn.comHLS Therapeutics appoints John Hanna as interim CFODecember 18, 2023 | finance.yahoo.comHLS Therapeutics Announces CFO DepartureDecember 11, 2023 | msn.com2 Top Pharmaceutical Stocks to Buy on the TSX TodayNovember 15, 2023 | finance.yahoo.comSome HLS Therapeutics Inc. (TSE:HLS) Analysts Just Made A Major Cut To Next Year's EstimatesNovember 14, 2023 | finance.yahoo.comNew REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at BaselineNovember 9, 2023 | marketwatch.comHLS Therapeutics Plans to Buyback Up to 5% of Its SharesNovember 9, 2023 | finance.yahoo.comHLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer BidNovember 9, 2023 | markets.businessinsider.comHLS Therapeutics earnings preview: what Wall Street is expectingOctober 2, 2023 | finance.yahoo.comEmergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of DirectorsSeptember 7, 2023 | finance.yahoo.comPositive Signs As Multiple Insiders Buy HLS Therapeutics StockSee More Headlines Receive HLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HLS Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today5/19/2024Next Earnings (Estimated)8/08/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:HLS CUSIPN/A CIKN/A Webwww.hlstherapeutics.com Phone647-495-9000FaxN/AEmployees91Year FoundedN/APrice Target and Rating Average Stock Price TargetC$3.88 High Stock Price TargetC$4.00 Low Stock Price TargetC$3.75 Potential Upside/Downside-1.6%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)C($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-27,530,000.00 Net Margins-43.65% Pretax MarginN/A Return on Equity-24.69% Return on Assets-2.87% Debt Debt-to-Equity Ratio89.69 Current Ratio1.65 Quick Ratio1.01 Sales & Book Value Annual SalesC$63.07 million Price / Sales1.99 Cash FlowC$0.26 per share Price / Cash Flow15.22 Book ValueC$3.06 per share Price / Book1.29Miscellaneous Outstanding Shares31,890,000Free FloatN/AMarket CapC$125.65 million OptionableNot Optionable Beta1.14 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Jason A. Gross Pharm.D. (Age 59)Vice President of Scientific Affairs Comp: $357.86kMr. Ryan C. Lennox B.A. (Age 43)J.D., Senior VP of Legal, HR & Compliance and Corporate Secretary Comp: $393.31kMr. Craig Stuart Millian M.B.A. (Age 56)CEO & Director Mr. John Hanna CPACGA, M.B.A., Interim CFO & Non-Independent DirectorBrian T. WalshSenior Vice President of CommercialMr. David Spence (Age 56)VP & Corporate Controller More ExecutivesKey CompetitorsMedexus PharmaceuticalsCVE:MDPBioSyentCVE:RXGreen Organic DutchmanTSE:TGODDelta 9 CannabisCVE:NINEWeedMDCVE:WMDView All CompetitorsInsidersCraig MillianBought 2,500 shares on 5/15/2024Total: C$7,250.00 ($2.90/share)Craig MillianBought 5,000 shares on 11/16/2023Total: C$13,000.00 ($2.60/share)Brian Thomas WalshBought 1,000 shares on 11/15/2023Total: C$2,910.00 ($2.91/share)Polar Asset Management Partners Inc.Bought 20,000 shares on 11/10/2023Total: C$86,000.00 ($4.30/share)Tim HendricksonBought 2,500 shares on 5/19/2023Total: C$11,250.00 ($4.50/share)View All Insider Transactions HLS Stock Analysis - Frequently Asked Questions Should I buy or sell HLS Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HLS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HLS, but not buy additional shares or sell existing shares. View HLS analyst ratings or view top-rated stocks. What is HLS Therapeutics' stock price target for 2024? 4 Wall Street analysts have issued 12 month price objectives for HLS Therapeutics' stock. Their HLS share price targets range from C$3.75 to C$4.00. On average, they anticipate the company's share price to reach C$3.88 in the next year. This suggests that the stock has a possible downside of 1.6%. View analysts price targets for HLS or view top-rated stocks among Wall Street analysts. How have HLS shares performed in 2024? HLS Therapeutics' stock was trading at C$3.95 on January 1st, 2024. Since then, HLS stock has decreased by 0.3% and is now trading at C$3.94. View the best growth stocks for 2024 here. When is HLS Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our HLS earnings forecast. How were HLS Therapeutics' earnings last quarter? HLS Therapeutics Inc. (TSE:HLS) posted its quarterly earnings data on Thursday, March, 14th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.05. The firm had revenue of $21.60 million for the quarter, compared to the consensus estimate of $21.83 million. HLS Therapeutics had a negative trailing twelve-month return on equity of 24.69% and a negative net margin of 43.65%. Is HLS Therapeutics a good dividend stock? HLS Therapeutics (TSE:HLS) pays an annual dividend of C$0.20 per share and currently has a dividend yield of 4.30%. HLS has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Read our dividend analysis for HLS. What other stocks do shareholders of HLS Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other HLS Therapeutics investors own include Cargojet (CJT), Fairfax Financial (FFH), Fortis (FTS), Aurora Cannabis (ACB), Aphria (APHA), Alimentation Couche-Tard (ATD.B), BlackBerry (BB), BCE (BCE), Bank of Montreal (BMO) and Bank of Nova Scotia (BNS). How do I buy shares of HLS Therapeutics? Shares of HLS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:HLS) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HLS Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.